AlphaMark Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

AlphaMark Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-195	Closed	-$5K	–	535
2019 Q1	$5K	Hold	195	–	–	﹤0.01%	412
2018 Q4	$4K	Hold	195	–	–	﹤0.01%	411
2018 Q3	$6K	Hold	195	–	–	﹤0.01%	412
2018 Q2	$9K	Buy	+195	New	+$9.48K	﹤0.01%	376
2017 Q3	–	Sell	-12	Closed	-$1K	–	552
2017 Q2	$1K	Buy	+12	New	+$734	﹤0.01%	524

Other funds holding CLVS

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

AlphaMark Advisors's CLVS Position: Q2 2019 in Review

AlphaMark Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q2 2019, closing a stake of 195 shares — an estimated $5K sold.

AlphaMark Advisors first reported a position in CLVS in Q2 2017 and held it in 5 quarters. The position peaked at $9K in Q2 2018. 167 funds tracked by Wall St. Rank hold CLVS as of Q2 2019.

AlphaMark Advisors reported no remaining Clovis Oncology, Inc. position as of Q2 2019 after selling out during the quarter.
AlphaMark Advisors sold 195 Clovis Oncology, Inc. shares in Q2 2019, an estimated $5K.
AlphaMark Advisors first reported a position in Clovis Oncology, Inc. in Q2 2017 and held it in 5 quarters.
AlphaMark Advisors's Clovis Oncology, Inc. position peaked at $9K in Q2 2018.
167 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2019.

Based on AlphaMark Advisors's 13F filing for Q2 2019, filed 2 Aug 2019.